Archived Bulletins

January 03, 2018

Published: January 03, 2018
Category: News

CCTG network researchers have been recognized by Governor General Julie Payette who announced the Order of Canada appointments on Friday, Dec. 29. Please join us in congratulating Dr. Pritchard, Dr. Gleave and Dr. Eisenhauer on this wonderful honour and for their outstanding contributions to cancer clinical trial research in Canada. Read more.

Read More

December 20, 2017

Published: December 20, 2017
Category: Trials
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
    Read More

    Published: December 20, 2017
    Category: Trials

    IND.234 - Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol has been centrally activated with participation limited to invited centres.

    Read More

    Published: December 20, 2017
    Category: News

    Happy holidays to all of our friends and colleagues from everyone at CCTG.

    Read More

    Published: December 20, 2017
    Category: Publications

    Links to online citations of previously published CCTG studies are listed here.

    Read More

    December 07, 2017

    Published: December 07, 2017
    Category: Group updates

    The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a Monitor/Auditor.

    Position Title: Monitor/Auditor
    Position Number: 00125702
    Employee Group: General Staff/Research - Office of Compliance and Oversight
    Salary Grade: 8

    Read More

    Published: December 07, 2017
    Category: Publications
    Citation for the primary publication for IND196
     
    Read More

    November 15, 2017

    Published: November 15, 2017
    Category: Trials

    The MEC.5 trial, A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma, is closed further accrual as of November 2nd, 2017. This trial met its accrual goal and was subsequently closed to registrations.

    Read More